Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

A year of the experimental treatment fenebrutinib suppressed nearly all disease activity in people with relapsing MS in a ...

Days after Sanofi reported back-to-back failures for its BTK inhibitor, Roche’s fenebrutinib on Wednesday scored a mid-stage ...

Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the ...

Roche has three ongoing Phase III trials of its BTK inhibitor fenebrutinib in patients with relapsing multiple sclerosis.

Roche is running three late-stage studies, namely FENhance 1 and 2 trials in relapsing MS, comparing the drug to Sanofi's Aubagio (teriflunomide) and the FENtrepid trial in primary progressive MS, ...

Fenebrutinib is a small molecule commercialized by Roche, with a leading Phase III program in Relapsing Multiple Sclerosis (RMS).

Swiss drugs and diagnostic maker, Roche (SIX:RO) is seeing mixed opinions from two big brokerages. BofA securities has ...

New Phase II data from Roche (ROG: SIX) show that fenebrutinib, a BTK inhibitor, achieved near-complete suppression of ...

Roche to present positive phase II FENopta OLE study data of BTK inhibitor, fenebrutinib to treat relapsing MS at 40th Congress of ECTRIMS: Basel Thursday, September 5, 2024, 13:0 ...